Healio: Eyevensys closes on $30 million Series B financing

Healio: Eyevensys closes on $30 million Series B financing

Healio: Eyevensys closes on $30 million Series B financing 150 150 Eyevensys

Patricia Zilliox, CEO of Eyevensys discusses closing a $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis.

Read More

Dallas News: Paris and Fort Worth-based biotech company Eyevensys raises $30 million to develop treatments for eye diseases
Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B
Start Typing